# REVELATION BIOSCIENCES, INC.

REVELATION BIOSCIENCES, INC. is an Asset Manager based in San Diego, United States.

## Overview

- **Organization type:** Asset Manager
- **Headquarters:** San Diego, United States
- **Region:** North America
- **Address:** San Diego, CA, United States
- **Founded:** 2020
- **Assets under management:** Undisclosed
- **Website:** revbiosciences.com

## Regulatory record

- **Reports private funds:** No

## About

Revelation Biosciences was incorporated in Delaware in 2020 and headquartered in San Diego, California. The company went public via a direct listing in January 2022, trading on Nasdaq under the ticker REVB. CEO James Rolke assumed the role in January 2024, succeeding the founding management team. The firm operates a hybrid model: it commercializes a topical antiseptic product while maintaining a legacy immunotherapy pipeline inherited from its predecessor entity. Revenue currently derives from REVSA-25, an over-the-counter povidone-iodine nasal swab launched under the commercial brand 'GermBlast Protect,' marketed for infection prevention. The biotech side of the business licenses and develops repurposed immunomodulators, with disclosed programs evaluating phosphorylated hexaacyl disaccharide (PHAD) in chronic kidney disease and acute kidney injury models. The firm has not publicly named co-development partners, co-investors, or large-scale institutional backers beyond its status as a Nasdaq-listed entity. Geographically, operations center on the US, with clinical and commercial activities run domestically. As a micro-cap public company with no disclosed institutional pharma partnerships, Revelation employs a lean outsourced development model to minimize cash burn. The company reported cash and equivalents of approximately $5.2 million as of its most recent SEC filing. An April 2025 1-for-12 reverse stock split allowed the firm to maintain Nasdaq listing compliance. Proceeds from periodic at-the-market equity offerings fund operations, with no venture-capital or single-family backing disclosed. Adjacent vehicles or philanthropic structures have not been identified. The firm's structural differentiator is its operational identity as a publicly traded asset manager within a biotech wrapper — revenue comes from an antiseptic swab, not a blockbuster drug, while the treasury is run with the liquidity-minded posture of a small registered fund. This dual track creates a capital structure where commercial hygiene-product sales and ATM equity issuances jointly sustain the clinical pipeline, rather than relying on milestone payments or large pharmaceutical alliances.

## Sectors

- Healthcare Services
- Digital Health

## People

- James Rolke — Chief Executive Officer
- Chester Zygmont — Chief Financial Officer

## Questions

### Does Revelation Biosciences generate operating revenue?

Yes. The firm markets REVSA-25, an OTC nasal antiseptic swab sold under the GermBlast Protect name, and reports commercial sales. Licensing income from its PHAD-based immunotherapy assets represents a secondary, intermittent revenue stream.

### How does Revelation source its therapeutic pipeline?

The clinical pipeline consists of repurposed immunomodulatory molecules licensed from earlier preclinical work, principally phosphorylated hexaacyl disaccharide (PHAD). The company does not operate in-house drug discovery and has not announced external acquisition transactions for new pipeline assets.

### What is the firm's known posture on co-investments alongside external partners?

No external co-investment partnerships with institutional allocators or venture capital firms have been disclosed. The company funds operations through product sales and equity market access, not via syndicated co-investment vehicles.

## Related profiles

- [Retirement Wealth Management](https://altss.com/profile/retirement-wealth-management-llc)
- [Revise Capital](https://altss.com/profile/revise-capital-llc)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/revelation-biosciences-inc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology